An update on hormone replacement therapy: Health and medicine for women: A multidisciplinary, evidence-based review of mid-life health concerns

Yale Journal of Biology and Medicine

Volumn 84, Issue 1, 2011, Pages 39-42

  Shook, Lydia L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ESTRADIOL; ESTROGEN; GESTAGEN; PLACEBO; TAMOXIFEN;

ATHEROSCLEROSIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RISK; CLINICAL EFFECTIVENESS; CORONARY ARTERY ATHEROSCLEROSIS; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; HEART DISEASE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; INTERDISCIPLINARY RESEARCH; LOW DRUG DOSE; MENOPAUSAL SYNDROME; NONHUMAN; REVIEW; TREATMENT PLANNING; WOMEN'S HEALTH; ARTICLE; FEMALE; MALE; MENOPAUSE; MIDDLE AGED; ORGANIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CONGRESSES AS TOPIC; EVIDENCE-BASED MEDICINE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MENOPAUSE; MIDDLE AGED; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WOMEN'S HEALTH;

EID: 79959784344     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Manson JE, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523-34.
2. Chlebowski RT, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289(24):3243-53.
3. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53(3):605-19.
4. Hsia J, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166(3):357-65.
5. Hulley S, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-13.
6. Clarkson TB, et al. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab. 2001;86(11):5396-404.
7. Stefanick ML, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295(14):1647-57.
8. Fournier A, et al. Unequal risks for breast cancer associated with different hormone eplacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-11.
9. Chlebowski RT, et al. Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women. JAMA. 2010;304(15):1684-92.
10. Stein R. Hormones also raise death risk of cancer. The Washington Post. 20 Oct. 2010. Available from: http://www.washingtonpost.com/wp-dyn/content/article/2010/10/19/AR2010101907522.html.
11. Soares CN, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58(6):529-34.
12. Rasgon NL, et al. Estrogen and response to sertraline in postmenopausal women with major depressive disorder: a pilot study. J Psychiatr Res. 2007;41(3-4):338-43.
13. Joffe H, et al. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause. 2006;13(3):411-22.
14. Shumaker SA, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291(24):2947-58.